Scotiabank Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price objective lowered by Scotiabank from $77.00 to $44.00 in a report released on Friday,Benzinga reports. The firm currently has a sector outperform rating on the stock.

Other equities analysts also recently issued research reports about the stock. Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. Wedbush reissued an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Guggenheim reissued a “buy” rating and issued a $102.00 price target (up from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.67.

Keros Therapeutics Trading Up 2.2 %

NASDAQ KROS opened at $18.83 on Friday. The firm has a market capitalization of $762.75 million, a PE ratio of -3.61 and a beta of 1.20. The business’s 50-day moving average price is $59.11 and its two-hundred day moving average price is $52.69. Keros Therapeutics has a 12 month low of $15.67 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million during the quarter. During the same quarter in the previous year, the firm earned ($1.33) EPS. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. As a group, analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its stake in shares of Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after purchasing an additional 32,492 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Keros Therapeutics during the 2nd quarter valued at approximately $1,118,000. Intech Investment Management LLC purchased a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $603,000. Bank of New York Mellon Corp increased its stake in shares of Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after purchasing an additional 18,755 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.